Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CENPF_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CENPF_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CENPF_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CENPF_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CENPF_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CENPF_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CENPF_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CENPF_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CENPF_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19058181 | Oral cavity | OSCC | regulation of chromosome separation | 47/7305 | 72/18723 | 5.69e-06 | 6.33e-05 | 47 |
GO:00109651 | Oral cavity | OSCC | regulation of mitotic sister chromatid separation | 43/7305 | 65/18723 | 8.50e-06 | 9.06e-05 | 43 |
GO:00300711 | Oral cavity | OSCC | regulation of mitotic metaphase/anaphase transition | 40/7305 | 60/18723 | 1.32e-05 | 1.33e-04 | 40 |
GO:0010389 | Oral cavity | OSCC | regulation of G2/M transition of mitotic cell cycle | 57/7305 | 94/18723 | 1.75e-05 | 1.71e-04 | 57 |
GO:00447841 | Oral cavity | OSCC | metaphase/anaphase transition of cell cycle | 42/7305 | 65/18723 | 2.57e-05 | 2.39e-04 | 42 |
GO:0051783 | Oral cavity | OSCC | regulation of nuclear division | 78/7305 | 139/18723 | 3.13e-05 | 2.86e-04 | 78 |
GO:000941018 | Oral cavity | OSCC | response to xenobiotic stimulus | 222/7305 | 462/18723 | 4.00e-05 | 3.48e-04 | 222 |
GO:20012512 | Oral cavity | OSCC | negative regulation of chromosome organization | 52/7305 | 86/18723 | 4.50e-05 | 3.84e-04 | 52 |
GO:19020991 | Oral cavity | OSCC | regulation of metaphase/anaphase transition of cell cycle | 40/7305 | 63/18723 | 7.19e-05 | 5.67e-04 | 40 |
GO:1902749 | Oral cavity | OSCC | regulation of cell cycle G2/M phase transition | 59/7305 | 102/18723 | 8.81e-05 | 6.72e-04 | 59 |
GO:00458392 | Oral cavity | OSCC | negative regulation of mitotic nuclear division | 32/7305 | 48/18723 | 9.60e-05 | 7.25e-04 | 32 |
GO:0051383 | Oral cavity | OSCC | kinetochore organization | 18/7305 | 23/18723 | 1.47e-04 | 1.04e-03 | 18 |
GO:0034508 | Oral cavity | OSCC | centromere complex assembly | 21/7305 | 30/18723 | 5.75e-04 | 3.30e-03 | 21 |
GO:00517842 | Oral cavity | OSCC | negative regulation of nuclear division | 34/7305 | 56/18723 | 8.17e-04 | 4.35e-03 | 34 |
GO:00330471 | Oral cavity | OSCC | regulation of mitotic sister chromatid segregation | 29/7305 | 46/18723 | 8.26e-04 | 4.38e-03 | 29 |
GO:00513041 | Oral cavity | OSCC | chromosome separation | 53/7305 | 96/18723 | 9.24e-04 | 4.86e-03 | 53 |
GO:0051382 | Oral cavity | OSCC | kinetochore assembly | 14/7305 | 18/18723 | 9.51e-04 | 4.96e-03 | 14 |
GO:00016558 | Oral cavity | OSCC | urogenital system development | 160/7305 | 338/18723 | 1.03e-03 | 5.31e-03 | 160 |
GO:00070941 | Oral cavity | OSCC | mitotic spindle assembly checkpoint | 24/7305 | 38/18723 | 2.21e-03 | 1.00e-02 | 24 |
GO:00711731 | Oral cavity | OSCC | spindle assembly checkpoint | 24/7305 | 38/18723 | 2.21e-03 | 1.00e-02 | 24 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CENPF | SNV | Missense_Mutation | novel | c.3773N>C | p.Ile1258Thr | p.I1258T | P49454 | protein_coding | tolerated(0.56) | benign(0.007) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
CENPF | SNV | Missense_Mutation | | c.2474N>T | p.Ser825Phe | p.S825F | P49454 | protein_coding | tolerated(0.41) | benign(0.187) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
CENPF | SNV | Missense_Mutation | novel | c.6094N>G | p.His2032Asp | p.H2032D | P49454 | protein_coding | tolerated(0.33) | benign(0.007) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
CENPF | SNV | Missense_Mutation | novel | c.938N>G | p.Asn313Ser | p.N313S | P49454 | protein_coding | tolerated(0.09) | benign(0.105) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
CENPF | SNV | Missense_Mutation | rs555088086 | c.1879N>A | p.Glu627Lys | p.E627K | P49454 | protein_coding | deleterious(0.05) | possibly_damaging(0.884) | TCGA-A8-A08G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
CENPF | SNV | Missense_Mutation | novel | c.41N>T | p.Thr14Ile | p.T14I | P49454 | protein_coding | deleterious(0.02) | benign(0.281) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CENPF | SNV | Missense_Mutation | | c.830N>T | p.Pro277Leu | p.P277L | P49454 | protein_coding | tolerated(0.09) | benign(0.001) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CENPF | SNV | Missense_Mutation | | c.3035C>T | p.Ser1012Leu | p.S1012L | P49454 | protein_coding | tolerated(0.12) | benign(0.386) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CENPF | SNV | Missense_Mutation | novel | c.5984A>C | p.Gln1995Pro | p.Q1995P | P49454 | protein_coding | deleterious(0.01) | benign(0.317) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CENPF | SNV | Missense_Mutation | novel | c.9248N>A | p.Ser3083Asn | p.S3083N | P49454 | protein_coding | tolerated(0.14) | benign(0.297) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |